Vita Coco Company, Inc. (COCO) · Oct 22, 2026 · Earnings
Beat — Revenue $243.8M vs ~$230.1M consensus
Vita Coco’s Q3 earnings beat revenue expectations, with organic growth still strong and full-year sales guidance raised despite a weak Q4 margin outlook.
Vita Coco is expanding from its flagship coconut-water brand into private label and the super-premium segment through July’s Copra acquisition, while riding strong category demand across the Americas and Europe. The filing says that strategy is working faster than expected in the quarter: organic sales growth remained 18% even excluding Copra, and management raised full-year sales guidance. The company’s broader strategy and Copra contribution were already known, so the surprise is the magnitude of underlying execution rather than the direction of travel.
The quarter clearly beat the market’s top-line expectation. Net sales rose 34% to $243.8 million, ahead of the published consensus of roughly $230.1 million, while diluted GAAP EPS increased to $0.58 from $0.40 a year earlier. The filing attributes the sales gain to 16% Vita Coco Coconut Water volume growth and 77% Private Label volume growth. 〔0〕
| Metric | Q3 2026 | Q3 2025 / prior reference | Read |
|---|---|---|---|
| Net sales | $243.8M | $182.3M | +34%; above ~$230.1M consensus |
| Organic net sales growth | 18% | — | Strong even excluding Copra |
| Diluted EPS | $0.58 | $0.40 | +45% year over year |
| Adjusted EBITDA | $53.2M | $32.4M | +64% year over year |
| Gross margin | 38.0% | 37.7% | Essentially flat in the quarter |
| FY2026 sales guidance | $810M–$820M | Prior: $790M–$805M | Raised |
The quality of growth is better than the headline acquisition boost suggests. Copra materially expanded Private Label sales, but management still reported 18% organic growth excluding the acquisition, above its own expectations. Private Label sales grew 152% in the quarter, while Vita Coco Coconut Water sales also advanced, showing that the core brand—not just the acquired business—is contributing to the upside. 〔1〕
Profitability improved sharply year to date, but the quarterly margin story is less clean. Adjusted EBITDA rose to $53 million from $32 million, and nine-month gross margin reached 42.2% versus 36.9% a year earlier, helped by tariff refunds and lower tariff costs. But Q3 gross margin was essentially flat at 38%, with higher domestic logistics costs and Copra’s mix offsetting the benefit. Management also expects Q4 gross margin to fall to approximately 33% before pricing actions begin in early 2027. 〔2〕
The higher outlook comes with a meaningful cash and integration trade-off. The company spent $139 million on Copra, repurchased $62 million of stock during the first nine months, and ended September with $152 million of cash and no debt. That leaves Vita Coco financially capable of funding the strategy, but with substantially less cash than at year-end and a $55 million seller earn-out recorded on the balance sheet.
Bottom line: This is a genuine earnings beat with strong organic momentum and a raised sales outlook, not merely an acquisition-driven quarter. The main complication is near-term margin pressure from Copra mix, freight and costs, making execution in Q4 and the planned 2027 pricing actions the next test of the story.
Q4 results; price actions expected in early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!